3D-Printed Template-Guided 125I Seed Brachytherapy: A Salvage Approach for Locoregional Refractory Recurrence of Papillary Thyroid Cancer.

IF 3.5 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM
European Thyroid Journal Pub Date : 2021-11-01 Epub Date: 2021-10-04 DOI:10.1159/000519572
Zhen Gao, Hongtao Zhang, Lijuan Zhang, Huimin Yu, Xuemin Di, Zeyang Wang, Zezhou Liu, Aixia Sui, Juan Wang, Gaofeng Shi
{"title":"3D-Printed Template-Guided <sup>125</sup>I Seed Brachytherapy: A Salvage Approach for Locoregional Refractory Recurrence of Papillary Thyroid Cancer.","authors":"Zhen Gao,&nbsp;Hongtao Zhang,&nbsp;Lijuan Zhang,&nbsp;Huimin Yu,&nbsp;Xuemin Di,&nbsp;Zeyang Wang,&nbsp;Zezhou Liu,&nbsp;Aixia Sui,&nbsp;Juan Wang,&nbsp;Gaofeng Shi","doi":"10.1159/000519572","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Papillary thyroid carcinoma (PTC) is typically treated with surgical resection, even in recurrent cases. However, some cases of recurrent PTC are refractory to the conventionally used locoregional radiotherapy and resection methods. <sup>125</sup>I seed permanent brachytherapy has emerged as a promising alternative for such PTCs, but no effective brachytherapy protocol has been reported for tumors with a huge volume, liquefaction, necrosis, and skin invasion.</p><p><strong>Case presentation: </strong>A 47-year-old man presented with recurrence 8 years after 2 thyroidectomy procedures for PTC and recurrent PTC. The tumor measured 6 × 7 × 8 cm<sup>3</sup> and exhibited liquefaction, necrosis, and skin invasion. The patient was treated at our hospital from December 2017 to November 2018. He received one round of <sup>125</sup>I seed temporary brachytherapy and 4 rounds of <sup>125</sup>I seed permanent implantation. The activity of the seeds was 0.3-3.0 mCi, and the total dose delivered to the tumor was 145 Gy. The recurrent tumor was successfully removed by <sup>125</sup>I seed brachytherapy guided with a 3D-printed template and ultrasound and CT scanning. The refractory tumor healed uneventfully after <sup>125</sup>I seed brachytherapy without recurrence over the 25-month follow-up.</p><p><strong>Conclusions: </strong>To the best of our knowledge, this is the first reported case of a large thyroid carcinoma that was effectively treated by 3D-printed template-guided <sup>125</sup>I seed brachytherapy.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":"10 6","pages":"504-510"},"PeriodicalIF":3.5000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647112/pdf/etj-0010-0504.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Thyroid Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000519572","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Papillary thyroid carcinoma (PTC) is typically treated with surgical resection, even in recurrent cases. However, some cases of recurrent PTC are refractory to the conventionally used locoregional radiotherapy and resection methods. 125I seed permanent brachytherapy has emerged as a promising alternative for such PTCs, but no effective brachytherapy protocol has been reported for tumors with a huge volume, liquefaction, necrosis, and skin invasion.

Case presentation: A 47-year-old man presented with recurrence 8 years after 2 thyroidectomy procedures for PTC and recurrent PTC. The tumor measured 6 × 7 × 8 cm3 and exhibited liquefaction, necrosis, and skin invasion. The patient was treated at our hospital from December 2017 to November 2018. He received one round of 125I seed temporary brachytherapy and 4 rounds of 125I seed permanent implantation. The activity of the seeds was 0.3-3.0 mCi, and the total dose delivered to the tumor was 145 Gy. The recurrent tumor was successfully removed by 125I seed brachytherapy guided with a 3D-printed template and ultrasound and CT scanning. The refractory tumor healed uneventfully after 125I seed brachytherapy without recurrence over the 25-month follow-up.

Conclusions: To the best of our knowledge, this is the first reported case of a large thyroid carcinoma that was effectively treated by 3D-printed template-guided 125I seed brachytherapy.

Abstract Image

Abstract Image

3d打印模板引导的125I粒子近距离放射治疗:局部难治性甲状腺乳头状癌复发的挽救方法。
背景:甲状腺乳头状癌(PTC)通常采用手术切除治疗,即使在复发病例中也是如此。然而,一些复发性PTC的病例对传统的局部放疗和切除方法是难以治愈的。125I种子永久性近距离治疗已成为此类ptc的一种有希望的替代方法,但对于体积巨大、液化、坏死和皮肤侵犯的肿瘤,尚无有效的近距离治疗方案报道。病例介绍:一名47岁男性,在两次甲状腺切除术后8年复发。肿瘤大小为6 × 7 × 8 cm3,表现为液化、坏死和皮肤浸润。患者于2017年12月至2018年11月在我院就诊。他接受了一轮125I粒子临时近距离治疗和4轮125I粒子永久植入。种子活性为0.3 ~ 3.0 mCi,总给药剂量为145 Gy。采用3d打印模板引导下的125I粒子近距离放射治疗,结合超声和CT扫描成功切除复发肿瘤。在25个月的随访中,顽固性肿瘤经125I粒子近距离治疗后无复发。结论:据我们所知,这是首例采用3d打印模板引导的125I粒子近距离放射治疗大甲状腺癌的报道。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Thyroid Journal
European Thyroid Journal Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
6.70
自引率
2.10%
发文量
156
期刊介绍: The ''European Thyroid Journal'' publishes papers reporting original research in basic, translational and clinical thyroidology. Original contributions cover all aspects of the field, from molecular and cellular biology to immunology and biochemistry, from physiology to pathology, and from pediatric to adult thyroid diseases with a special focus on thyroid cancer. Readers also benefit from reviews by noted experts, which highlight especially active areas of current research. The journal will further publish formal guidelines in the field, produced and endorsed by the European Thyroid Association.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信